doi: 10.1016/j.joim.2018.04.007, 8
Lancet 1998;351:637-41
Wh-ereas the three studies finding a significant therapeutic efficacy of the COX-2 inhibitor were based on patients with a short illness period,113114115 the one study with a negative result was conducted with patients with relatively chronic schizophrenia.116 A meta-analysis showed that augmentation of anti-inflammatory drugs to the antipsychotics would be a potential therapeutic options in patients with schizophrenia, although more evidences should be accumulated.117 Several antioxidant treatment approaches have reported that antioxidants are effective for improving psychopathology in schizophrenia
Disclosure of interest: Isehaq Al jabri: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.07 - SMALL VESSEL DISEASE P2408 - ESOC25-2000 CERERBAL AMYLOID ANGIOPATHY AND AMYLOID LOAD DISTRIBUTION DETECTED ON AMYLOIDPOSITRON EMISSION TOMOGRAPHY: A SYSTEMATIC REVIEW AND META-ANALYSIS Aikaterini Theodorou 1 , Konstantinos Melanis 1 , Athanasia Athanasaki 1 , Eleni Bakola 1 , Maria Chondrogianni 1 , Vasiliki Kotsali-Peteinelli 1 , Georgia Papagiannopoulou 1 , Anna Keramida 1 , Efthimios Vasilopoulos 2 , Anastasios Kouzoupis 2 , Georgios Velonakis 3 , Foteini Boufidou 4 , George Paraskevas 1 , Ilias Tzavellas 2 , Georgios Tsivgoulis 1 1 Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2 First Department of Psychiatry, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 3 Second Department of Radiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 4 First Department of Neurology, "Eginition" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Background and Aims: There are limited data regarding the amyloid positron emission tomography (PET) imaging among patients with Cerebral Amyloid Angiopathy (CAA)
In clinical validation, this test achieved 91.7% concordance with PET-confirmed amyloid positivity and 97.3% concordance with PET negativity, with only ~20% of results deemed indeterminate
For other people, that's not manageable or safe and so on
